This HTML5 document contains 65 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n21http://linked.opendata.cz/resource/drugbank/drug/DB00185/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00185/identifier/national-drug-code-directory/
n4http://linked.opendata.cz/resource/mesh/concept/
n13http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00185/identifier/chebi/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n19http://www.rxlist.com/cgi/generic/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00185/identifier/wikipedia/
n12http://linked.opendata.cz/resource/drugbank/patent/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00185/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/mesh/
n11http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00185/identifier/kegg-drug/
n25http://linked.opendata.cz/resource/atc/
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00185
rdf:type
n5:Drug
n5:description
Cevimeline is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome. [Wikipedia]
n5:dosage
n13:271B543E-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
5 ± 1 hours
n5:indication
For the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome.
n5:manufacturer
n7:271B543C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00185 n26:DB00185
dcterms:title
Cevimeline
adms:identifier
n16:D00661 n17:63395-201-13 n18:3568 n21:DB00185 n22:PA164754754 n23:Cevimeline
n5:mechanismOfAction
Muscarinic agonists such as cevimeline bind and activate the muscarinic M1 and M3 receptors. The M1 receptors are common in secretory glands (exocrine glands such as salivary and sweat glands), and their activation results in an increase in secretion from the secretory glands. The M3 receptors are found on smooth muscles and in many glands which help to stimulate secretion in salivary glands, and their activation generally results in smooth muscle contraction and increased glandular secretions. Therefore, as saliva excretion is increased, the symptoms of dry mouth are relieved.
n5:packager
n7:271B543A-363D-11E5-9242-09173F13E4C5 n7:271B543B-363D-11E5-9242-09173F13E4C5
n5:patent
n12:4855290 n12:5340821
n5:routeOfElimination
After 24 hours, 84% of a 30 mg dose of cevimeline was excreted in urine.
n5:synonym
Cevimelina Cevimelinum 2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine Sni 2011
n5:volumeOfDistribution
* 6 L/kg
n5:proteinBinding
< 20%
n5:salt
n3:hasConcept
n4:M0164858
foaf:page
n11:cevimeline.html n19:cevimeline.htm
n5:IUPAC-Name
n6:271B5443-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5449-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5448-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5445-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5446-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5447-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5458-363D-11E5-9242-09173F13E4C5 n6:271B5441-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B545A-363D-11E5-9242-09173F13E4C5 n6:271B543F-363D-11E5-9242-09173F13E4C5 n6:271B5442-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5440-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n25:N07AX03
n5:H-Bond-Acceptor-Count
n6:271B544F-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5450-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B544A-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B544B-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B544D-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B544C-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B544E-363D-11E5-9242-09173F13E4C5
n5:absorption
Rapidly absorbed with peak concentration after 1.5 to 2 hours
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
107233-08-9
n5:containedIn
n20:271B543D-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B5454-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5456-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5457-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B5459-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5453-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5452-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5455-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5444-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5451-363D-11E5-9242-09173F13E4C5